The survival curves showed that CRC patients with high NAT2 expression had a better prognosis than those with low NAT2 expression (Figures 3I,J), which were consistent with the results from the GEPIA-CRC expression profile. The gene discussed is NAT2; the disease is colorectal carcinoma.